Shanghai HeartCare Medical Technology Corporation Limited (HKG:6609)
56.15
+5.45 (10.75%)
At close: Jan 21, 2026
HKG:6609 Revenue
Shanghai HeartCare Medical Technology Corporation had revenue of 185.52M CNY in the half year ending June 30, 2025, with 69.29% growth. This brings the company's revenue in the last twelve months to 334.94M, up 33.31% year-over-year. In the year 2024, Shanghai HeartCare Medical Technology Corporation had annual revenue of 277.90M with 19.61% growth.
Revenue (ttm)
334.94M CNY
Revenue Growth
+33.31%
P/S Ratio
5.81
Revenue / Employee
973.65K CNY
Employees
344
Market Cap
2.13B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 277.90M | 45.56M | 19.61% |
| Dec 31, 2023 | 232.34M | 49.31M | 26.94% |
| Dec 31, 2022 | 183.03M | 92.94M | 103.17% |
| Dec 31, 2021 | 90.09M | 75.53M | 518.66% |
| Dec 31, 2020 | 14.56M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 38.69B |
| Alibaba Health Information Technology | 36.09B |
| Sino Biopharmaceutical | 33.49B |
| CSPC Pharmaceutical Group | 28.65B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |